THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM
Publication
, Conference
Gellad, ZF; Naggie, S; Reed, SD; Clark, PJ; Thompson, AJ; Schulman, KA; Muir, AJ
Published in: HEPATOLOGY
October 1, 2011
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2011
Volume
54
Start / End Page
417A / 418A
Location
San Francisco, CA
Publisher
WILEY-BLACKWELL
Conference Name
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Gellad, Z. F., Naggie, S., Reed, S. D., Clark, P. J., Thompson, A. J., Schulman, K. A., & Muir, A. J. (2011). THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM. In HEPATOLOGY (Vol. 54, pp. 417A-418A). San Francisco, CA: WILEY-BLACKWELL.
Gellad, Ziad F., Susanna Naggie, Shelby D. Reed, Paul J. Clark, Alex J. Thompson, Kevin A. Schulman, and Andrew J. Muir. “THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM.” In HEPATOLOGY, 54:417A-418A. WILEY-BLACKWELL, 2011.
Gellad ZF, Naggie S, Reed SD, Clark PJ, Thompson AJ, Schulman KA, et al. THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM. In: HEPATOLOGY. WILEY-BLACKWELL; 2011. p. 417A-418A.
Gellad, Ziad F., et al. “THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM.” HEPATOLOGY, vol. 54, WILEY-BLACKWELL, 2011, pp. 417A-418A.
Gellad ZF, Naggie S, Reed SD, Clark PJ, Thompson AJ, Schulman KA, Muir AJ. THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM. HEPATOLOGY. WILEY-BLACKWELL; 2011. p. 417A-418A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2011
Volume
54
Start / End Page
417A / 418A
Location
San Francisco, CA
Publisher
WILEY-BLACKWELL
Conference Name
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics